FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317488951> ?p ?o ?g. }

• W4317488951 endingPage "633" @default.
• W4317488951 startingPage "621" @default.
• W4317488951 abstract "Background Developing a safe and immunogenic vaccine against Zika virus remains an unmet medical need. We did two phase 1 studies that evaluated the safety and immunogenicity of two mRNA-based Zika virus vaccines (mRNA-1325 and mRNA-1893) in adults. Methods Two randomised, placebo-controlled, dose-ranging, multicentre, phase 1 trials, one of mRNA-1325 (mRNA-1325 trial) and one of mRNA-1893 (mRNA-1893 trial), were done. For both studies, eligible participants were healthy adults (aged 18–49 years) who were flavivirus seronegative or flavivirus seropositive at baseline. Participants in the mRNA-1325 trial, which was done at three centres in the USA, were randomly assigned centrally (1:4), using a randomisation table, to the placebo group or one of three mRNA-1325 dose groups (10, 25, or 100 μg). All participants received two doses. The mRNA-1325 vaccine encoded the premembrane and envelope E structural proteins (prME) from a Micronesia 2007 Zika virus isolate. Participants in the mRNA-1893 trial, which was done at three centres in the USA and one centre in Puerto Rico, were randomly assigned (1:4) to the placebo group or one of four mRNA-1893 dose groups (10, 30, 100, or 250 μg) using centralised interactive response technology. All participants in the mRNA-1893 trial received dose one on day 1 and then dose two on day 29. The mRNA-1893 vaccine encoded the prME from the RIO-U1 Zika virus isolate. Safety was the primary outcome of each study, which was evaluated in the respective safety populations (mRNA-1325 trial: participants who received at least one dose and provided safety data; mRNA-1893 trial: participants who received at least one dose) and the solicited safety population (mRNA-1893 trial only: received at least 1 dose and contributed solicited adverse reaction data). Endpoints in both trials included solicited adverse reactions within 7 days after vaccination and unsolicited adverse events within 28 days after vaccination. The secondary outcome of both trials was immunogenicity assessed by Zika virus-specific neutralising antibodies (nAbs) in the per-protocol populations in either trial (participants with no major protocol deviations received full dose[s] of assigned dose level within the acceptable time window, had samples drawn within acceptable time window, and had prevaccination and corresponding post-vaccination serum samples for testing). These were descriptive studies, with no formal hypothesis testing in either trial. Both trials are registered with ClinicalTrials.gov, NCT03014089 (mRNA-1325 trial) and NCT04064905 (mRNA-1893 trial). Findings The mRNA-1325 trial was done from Dec 14, 2016, to Aug 16, 2018. 90 participants were enrolled: 53 (59%) participants were women and 37 (41%) were men; 84 (93%) were White; and 74 (82%) were not Hispanic or Latino. All three dose levels of mRNA-1325 (10, 25, and 100 μg) were generally well tolerated, but the vaccine elicited poor Zika virus-specific nAb responses. At 28 days after dose two, geometric mean titres (GMTs) were highest for mRNA-1325 10 μg (10·3 [95% CI 5·9–18·2]). The mRNA-1893 trial was done from July 23, 2019, to March 22, 2021. 120 participants (70 [58%] women and 50 [42%] men) were enrolled, most participants were White (89 [74%]), and not Hispanic or Latino (91 [76%]). In the mRNA-1893 trial, solicited adverse reactions in participants who received a vaccine were mostly grade 1 or 2 and occurred more frequently at higher dose levels and after dose two. No participants withdrew due to an unsolicited treatment-emergent adverse event and most of these events were not treatment related. On day 57, all evaluated mRNA-1893 dose levels induced robust Zika virus-specific nAb responses, independent of flavivirus serostatus, that persisted until month 13. At day 57 in participants who were flavivirus seronegative, plaque reduction neutralisation titre test nAb GMTs were highest for mRNA-1893 100 μg (454·2 [330·0–619·6]); in participants who were flavivirus seropositive, GMTs were highest for mRNA-1893 10 μg (224·1 [43·5–1153·5]) and mRNA-1893 100 μg (190·5 [19·2–1887·2]). Interpretation These findings support the continued development of mRNA-1893 against Zika virus, which was well tolerated at all evaluated dose levels and induced strong Zika virus-specific serum nAb responses after two doses, regardless of baseline flavivirus serostatus. Funding Biomedical Advanced Research and Development Authority and Moderna." @default.
• W4317488951 created "2023-01-20" @default.
• W4317488951 creator A5010712508 @default.
• W4317488951 creator A5014661915 @default.
• W4317488951 creator A5023317744 @default.
• W4317488951 creator A5031923074 @default.
• W4317488951 creator A5039188670 @default.
• W4317488951 creator A5039671566 @default.
• W4317488951 creator A5041305080 @default.
• W4317488951 creator A5045201341 @default.
• W4317488951 creator A5059396155 @default.
• W4317488951 creator A5061349411 @default.
• W4317488951 creator A5063553781 @default.
• W4317488951 creator A5064664004 @default.
• W4317488951 creator A5069914051 @default.
• W4317488951 creator A5078242503 @default.
• W4317488951 date "2023-05-01" @default.
• W4317488951 modified "2023-10-15" @default.
• W4317488951 title "The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials" @default.
• W4317488951 cites W2033094913 @default.
• W4317488951 cites W2122349387 @default.
• W4317488951 cites W2311276862 @default.
• W4317488951 cites W2460107925 @default.
• W4317488951 cites W2462844494 @default.
• W4317488951 cites W2546845633 @default.
• W4317488951 cites W2586860795 @default.
• W4317488951 cites W2587850379 @default.
• W4317488951 cites W2771066123 @default.
• W4317488951 cites W2804938199 @default.
• W4317488951 cites W2884368199 @default.
• W4317488951 cites W2920135474 @default.
• W4317488951 cites W2977494746 @default.
• W4317488951 cites W3007687715 @default.
• W4317488951 cites W3032674291 @default.
• W4317488951 cites W3080379602 @default.
• W4317488951 cites W3087018937 @default.
• W4317488951 cites W3107741684 @default.
• W4317488951 cites W3109622797 @default.
• W4317488951 cites W3112391456 @default.
• W4317488951 cites W3128853581 @default.
• W4317488951 cites W3188940990 @default.
• W4317488951 cites W3199784607 @default.
• W4317488951 cites W4205483821 @default.
• W4317488951 doi "https://doi.org/10.1016/s1473-3099(22)00764-2" @default.
• W4317488951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36682364" @default.
• W4317488951 hasPublicationYear "2023" @default.
• W4317488951 type Work @default.
• W4317488951 citedByCount "9" @default.
• W4317488951 countsByYear W43174889512023 @default.
• W4317488951 crossrefType "journal-article" @default.
• W4317488951 hasAuthorship W4317488951A5010712508 @default.
• W4317488951 hasAuthorship W4317488951A5014661915 @default.
• W4317488951 hasAuthorship W4317488951A5023317744 @default.
• W4317488951 hasAuthorship W4317488951A5031923074 @default.
• W4317488951 hasAuthorship W4317488951A5039188670 @default.
• W4317488951 hasAuthorship W4317488951A5039671566 @default.
• W4317488951 hasAuthorship W4317488951A5041305080 @default.
• W4317488951 hasAuthorship W4317488951A5045201341 @default.
• W4317488951 hasAuthorship W4317488951A5059396155 @default.
• W4317488951 hasAuthorship W4317488951A5061349411 @default.
• W4317488951 hasAuthorship W4317488951A5063553781 @default.
• W4317488951 hasAuthorship W4317488951A5064664004 @default.
• W4317488951 hasAuthorship W4317488951A5069914051 @default.
• W4317488951 hasAuthorship W4317488951A5078242503 @default.
• W4317488951 hasConcept C126322002 @default.
• W4317488951 hasConcept C142724271 @default.
• W4317488951 hasConcept C159047783 @default.
• W4317488951 hasConcept C159654299 @default.
• W4317488951 hasConcept C168563851 @default.
• W4317488951 hasConcept C203014093 @default.
• W4317488951 hasConcept C204787440 @default.
• W4317488951 hasConcept C2522874641 @default.
• W4317488951 hasConcept C27081682 @default.
• W4317488951 hasConcept C2777053367 @default.
• W4317488951 hasConcept C2780568436 @default.
• W4317488951 hasConcept C2780868878 @default.
• W4317488951 hasConcept C535046627 @default.
• W4317488951 hasConcept C71924100 @default.
• W4317488951 hasConceptScore W4317488951C126322002 @default.
• W4317488951 hasConceptScore W4317488951C142724271 @default.
• W4317488951 hasConceptScore W4317488951C159047783 @default.
• W4317488951 hasConceptScore W4317488951C159654299 @default.
• W4317488951 hasConceptScore W4317488951C168563851 @default.
• W4317488951 hasConceptScore W4317488951C203014093 @default.
• W4317488951 hasConceptScore W4317488951C204787440 @default.
• W4317488951 hasConceptScore W4317488951C2522874641 @default.
• W4317488951 hasConceptScore W4317488951C27081682 @default.
• W4317488951 hasConceptScore W4317488951C2777053367 @default.
• W4317488951 hasConceptScore W4317488951C2780568436 @default.
• W4317488951 hasConceptScore W4317488951C2780868878 @default.
• W4317488951 hasConceptScore W4317488951C535046627 @default.
• W4317488951 hasConceptScore W4317488951C71924100 @default.
• W4317488951 hasIssue "5" @default.
• W4317488951 hasLocation W43174889511 @default.
• W4317488951 hasLocation W43174889512 @default.
• W4317488951 hasOpenAccess W4317488951 @default.
• W4317488951 hasPrimaryLocation W43174889511 @default.
• W4317488951 hasRelatedWork W2321941411 @default.

• next